All 16 of the drug manufacturers that signed deals with Trump have issued price hikes this year, according to reports.

The loss of market exclusivity for a trio of big-selling drugs in the last quarter of 2025 dragged down Novartis sales, but chief executive Vas Narasimhan says the company is equipped to ride out "the ...